HomeCompareXELA vs MRK

XELA vs MRK: Dividend Comparison 2026

XELA yields 4000.00% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 XELA wins by $7175340620755.81M in total portfolio value
10 years
XELA
XELA
● Live price
4000.00%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7175340620755.87M
Annual income
$6,839,006,593,197,835,000.00
Full XELA calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — XELA vs MRK

📍 XELA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodXELAMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, XELA + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
XELA pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

XELA
Annual income on $10K today (after 15% tax)
$340,000.00/yr
After 10yr DRIP, annual income (after tax)
$5,813,155,604,218,160,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, XELA beats the other by $5,813,155,604,218,152,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of XELA + MRK for your $10,000?

XELA: 50%MRK: 50%
100% MRK50/50100% XELA
Portfolio after 10yr
$3587670310377.96M
Annual income
$3,419,503,296,598,923,000.00/yr
Blended yield
95.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

XELA
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
Price Target
$70.00
+139900.0% upside vs current
Range: $70.00 — $70.00
Altman Z
-3.5
Piotroski
6/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

XELA buys
0
MRK buys
0
No recent congressional trades found for XELA or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricXELAMRK
Forward yield4000.00%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$7175340620755.87M$56.8K
Annual income after 10y$6,839,006,593,197,835,000.00$9,798.13
Total dividends collected$7152397773804.84M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$70.00$128.54

Year-by-year: XELA vs MRK ($10,000, DRIP)

YearXELA PortfolioXELA Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$410,700$400,000.00$11,206$366.19+$399.5KXELA
2$15,792,720$15,353,271.03$12,650$502.35+$15.78MXELA
3$568,657,142$551,758,931.89$14,407$694.19+$568.64MXELA
4$19,176,207,860$18,567,744,718.20$16,585$967.82+$19176.19MXELA
5$605,696,028,890$585,177,486,479.73$19,342$1,363.89+$605696.01MXELA
6$17,922,210,653,594$17,274,115,902,681.27$22,913$1,947.19+$17922210.63MXELA
7$496,869,793,504,300$477,693,028,104,954.00$27,662$2,823.89+$496869793.48MXELA
8$12,908,672,105,251,704$12,377,021,426,202,104.00$34,159$4,173.35+$12908672105.22MXELA
9$314,330,866,876,668,540$300,518,587,724,049,200.00$43,337$6,308.80+$314330866876.63MXELA
10$7,175,340,620,755,871,000$6,839,006,593,197,835,000.00$56,776$9,798.13+$7175340620755.81MXELA

XELA vs MRK: Complete Analysis 2026

XELAStock

Exela Technologies, Inc. provides transaction processing solutions, enterprise information management, document management, and digital business process services worldwide. The company operates through three segments: Information & Transaction Processing Solutions (ITPS), Healthcare Solutions (HS), and Legal & Loss Prevention Services (LLPS). The ITPS segment provides lending solutions for mortgages and auto loans; banking solutions for clearing, anti-money laundering, sanctions, and interbank cross-border settlement; property and casualty insurance solutions for origination, enrollments, claims processing, and benefits administration communications; and public sector solutions for income tax processing, benefits administration, and records management. It also offers solutions for payment processing and reconciliation, integrated receivable and payables management, document logistics and location services, records management, and electronic storage of data/documents; and software, hardware, professional services, and maintenance related to information and transaction processing automation. The HS segment provides revenue cycle solutions, integrated accounts payable and accounts receivable, and information management for healthcare payer and provider markets. The LLPS segment processes legal claims for class action and mass action settlement administrations, involving project management support, notification, and outreach to claimants; and collects, analyzes, and distributes settlement funds. It also offers data and analytical services in the areas of litigation consulting, economic and statistical analysis, expert witness services, and revenue recovery services for delinquent accounts receivable. The company is headquartered in Irving, Texas.

Full XELA Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this XELA vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

XELA vs SCHDXELA vs JEPIXELA vs OXELA vs KOXELA vs MAINXELA vs JNJXELA vs ABBVXELA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.